OBARCORT 40 mg, a medication that belongs to the class of corticosteroids with anti-inflammatory properties. It is primarily used in the treatment of various inflammatory conditions and autoimmune diseases.

OBARCORT 40 mg is highly effective in reducing redness and swelling, as well as reducing pain and irritation caused by numerous inflammatory conditions.

OBARCORT 40 mg can be used as an intra-articular injection or as an intramuscular injection.

Each 1 mL of the sterile aqueous suspension of OBARCORT 40 mg contains 40 mg Triamcinolone acetonide.

By Intramuscular Route:

OBARCORT 40 mg Ampoules are primarily used in the following conditions:

Allergic states:

Bronchial asthma, contact dermatitis, atopic dermatitis, seasonal or perennial allergic rhinitis.

Dermatologic diseases:

Pemphigus, severe erythema multiforme, exfoliative dermatitis, bullous dermatitis herpetiformis, severe seborrheic dermatitis, severe psoriasis.

Collagen diseases:

During an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus, acute rheumatic carditis.

Endocrine disorders:

Nonsuppurative thyroiditis.

Hematologic disorders:

Acquired hemolytic anemia.

Neoplastic diseases:

For palliative management of leukemias and lymphomas in adults, acute leukemia of childhood.

Edematous state:

To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.

Ophthalmic diseases:

Severe chronic allergic and inflammatory processes involving the eye, such as herpes zoster ophthalmicus, iritis, iridocyclitis, chorioretinitis, diffuse posterior uveitis and choroiditis, optic neuritis, sympathetic ophthalmia, anterior segment inflammation.

Respiratory diseases:

Symptomatic sarcoidosis, berylliosis, aspiration pneumonitis.

Rheumatic disorders:

As adjunctive therapy for short-term administration in: posttraumatic osteoarthritis, synovitis of osteoarthritis, rheumatoid arthritis, acute and subacute bursitis, epicondylitis, acute nonspecific tenosynovitis, acute gouty arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile, rheumatoid arthritis.

By Intra-Articular Route:

OBARCORT 40 mg injection is indicated for intra-articular or intrabursal administration, and for injections into tendon sheaths, as adjunctive therapy for short-term administration in:

Synovitis of osteoarthritis

Rheumatoid arthritis

Acute and subacute bursitis

Acute gouty arthritis

Epicondylitis

Acute nonspecific tenosynovitis

Posttraumatic osteoarthritis

Children:

OBARCORT 40 mg is not indicated for use in children under 6 years of age.

Pregnancy& breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking OBARCORT 40 mg.

Infants born to mothers who have received substantial doses of OBARCORT 40 mg during pregnancy should be carefully observed for signs of hypoadrenalism.

Pregnancy Category: C.

OBARCORT 40 mg should not be used whilst breastfeeding because of small amounts OBARCORT 40 mg appear in breast milk, which may lead to growth Suppression, affect the production of endogenous corticosteroids, and cause other side effects.

Systemic:

For adults and children over 12 years of age:

The suggested initial dose of OBARCORT 40 mg is one and ½ ampoule (60 mg), injected deeply into the gluteal muscle. Subcutaneous fat atrophy may occur if care is not taken to inject the preparation intramuscularly.

The recommended dose of OBARCORT 40 mg is one ampoule (40 mg) to two ampoules (80 mg), depending upon the patient's response and the duration of symptom relief after injection.

Some patients may be adequately controlled on lower doses, such as ½ ampoule (20 mg) or less.

Patients with hay fever or pollen asthma who do not respond to pollen administration and other conventional therapies may experience symptom remission lasting throughout the pollen season after a single dose ranging from one ampoule (40 mg) to tow and ½ ampoules (100 mg).

For children from 6 to 12 years of age:

The suggested initial dose of OBARCORT 40 mg is one ampoule. However, the dose depends more on the severity of symptoms than on the patient’s age or weight.

Local:

For intra-articular or intrabursal administration, and for injection into tendon sheaths, the initial dose of OBARCORT 40 mg injection may vary from 2.5 mg to 5 mg for smaller joints, and from 5 mg to 15 mg for larger joints, depending on the specific disease entity being treated.

For adults, doses up to 10 mg for smaller areas and up to 40 mg for larger areas have generally been sufficient to alleviate symptoms.

Single injections of OBARCORT 40 mg into multiple joints for multiple locus involvement up to a total of two ampoules (80 mg), have been given without undue reactions. A single local injection of OBARCORT 40 mg is frequently sufficient, but several injections may be needed for adequate relief of symptom.

The lower doses in the initial dosage range of OBARCORT 40 mg may produce the desired effect when the corticosteroid is administered to provide a localized concentration.

The injection site and injection volume should be carefully considered carefully when OBARCORT 40 mg is administering for this purpose.